Disease · MONDO_0005438
metastatic malignant neoplasm in the lymph nodes
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. metastatic malignant neoplasm in the lymph nodes. Diseases, record MONDO_0005438. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005438
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Metastases to lymph nodes, lymph node metastatic carcinoma, metastasis to lymph node, metastatic malignant neoplasm to the lymph nodes, metastatic neoplasm to the lymph node, metastatic tumor to lymph node, metastatic tumour to lymph node
- Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEMETREXED | CHEMBL225072 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SINTILIMAB | CHEMBL4297829 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 19
See all 19 targetsTrials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00590967 | A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy | Phase 2 | 69 | 2016-08-29 | Cervical Cancer | CISPLATIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00030771 | Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients | Phase 3 | 232 | Lung Cancer | CISPLATIN, DOCETAXEL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT07309952 | Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC | Phase 2 | 28 | Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer | CARBOPLATIN, PACLITAXEL, PEMETREXED, SINTILIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02441270 | Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients | Early phase 1 | 0 | Radiotherapy, Immunology | CYCLOPHOSPHAMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) vs Treatment Group 2 (IMRT, Brachytherapy, Cisplatin): serious adverse events | 10 of 41 | 4 of 20 | 61 | NCT00590967 |
Source Trial comparisons
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 26275735 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005438
GET https://conductscience.org/api/diseases/v1/MONDO_0005438/drugs